To include your compound in the COVID-19 Resource Center, submit it here.

Sanofi declines option for Voyager's PD gene therapy

The Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) declined to exercise its exclusive option to obtain ex-U.S. rights to VY-AADC-01 from Voyager Therapeutics Inc. (NASDAQ:VYGR) to treat Parkinson’s disease.

According

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE